Clinical Usefulness of the 2010 Clinical and Laboratory Standards Institute Revised Breakpoints for Cephalosporin Use in the Treatment of Bacteremia Caused by Escherichia coli or Klebsiella spp.

Table 2

Demographic and clinical characteristics of 573 patients with E. coli or Klebsiella spp. Bacteremia.

Variables	Number (%)
Mean age (range, years)	65.51 (24–92)
Male	291 (50.8)
Hospital acquired	105 (18.3)
Community acquired	468 (81.7)
Underlying disease
Malignancy
Solid	249 (43.5)
Hematologic	14 (2.4)
Transplantation
Solid	5 (0.9)
Hematopoietic stem cell	0 (0.0)
Diabetes	169 (29.5)
Cardiovascular disease	261 (45.5)
Chronic lung disease	4 (0.7)
Chronic renal disease	23 (4.0)
Chronic liver disease	58 (10.1)
HIV infection	1 (0.1)
Route of infection
Urinary tract infection	164 (28.6)
Liver abscess	40 (7.0)
Pancreatobiliary infection	267 (46.6)
Pulmonary infection	17 (3.0)
Peritonitis	18 (3.1)
Primary bacteremia	54 (9.4)
Other	13 (2.3)
Charlson index, mean ± SD	2.63 ± 2.278
SOFA score, mean ± SD	3.02 ± 2.493
ESBL-producing isolates	10 (1.7)
28-day mortality	29 (5.1)

ESBL, extended-spectrum -lactamase; HIV, human immunodeficiency syndrome; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.